- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07654348
Efficacy and Mechanism of IPSRT for Bipolar II Disorder
The Efficacy and Mechanism of Different Intervention Strategy for Bipolar II Disorder Patients With Rhythm Disturbance
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Huang Manli, Professor
- Telefoonnummer: 13957162975 Ext. 86
- E-mail: huangmanli@zju.edu.cn
Studie Locaties
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- The First Affiliated Hospital of Zhejiang University
-
Contact:
- Huang Manli, M.D
- Telefoonnummer: 13957162975 Ext. 86
- E-mail: huangmanli@zju.edu.cn
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
1: a primary diagnosis of bipolar II disorder in accordance with DSM-V criteria, in a current major depressive episode;
2: scoring ≥17 on the 17-item Hamilton Rating Scale for Depression (HAMD-17)
3: scoring <12 on the Young Mania Rating Scale (YMRS)
4: medication-free (≥4 weeks without psychotropics)
5: with rhythm disturbance, scoring >26 on the Biological Rhythm Interview for Neuropsychiatry (BRIAN)
6: Understand written language and be able to conduct questionnaire survey
7: 18 to 60 years old, gender is not limited
8: the patient voluntarily participates, signs a written informed consent form, is willing to participate in the study and undergo evaluation
9: Han Chinese
10: Right-handedness
Exclusion Criteria:
1: diseases that may significantly increase research risks or interfere with the evaluation of results
2: patients with rapid-cycling bipolar disorder (with >4 episodes within the past year);
3: any psychiatric or organic mental disorder, bipolar I disorder (BD I), current alcohol or drug dependence, borderline or antisocial personality disorder
4: patients currently receiving any psychological treatment or melatonin treatment intervention
5: patients with active suicidal ideation, HAMD-17 item 3 score ≥3
6: pregnant
7: patients with metal objects in the body (pacemaker, cochlear implant, implanted teeth, braces, metal foreign bodies, cardiac stent/intravascular coil, orthopedic steel plate, etc.) and other MRI examination contraindications (claustrophobia or inability to cooperate with the examination).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Group Q
Patients received treatment with quetiapine alone (starting at 50mg/day, with an additional 50mg to 300mg/day per week, and the dosage can be flexibly adjusted)
|
Patients received treatment with quetiapine alone (starting at 50mg/day, with an additional 50mg to 300mg/day per week, and the dosage can be flexibly adjusted)
|
|
Experimenteel: Group I
Patients received 12 weeks of interpersonal and social rhythm therapy (12 sessions, once a week, 40 minutes each time, with relatively fixed tasks and agendas for each meeting)
|
Patients received 12 weeks of interpersonal and social rhythm therapy (12 sessions, once a week, 40 minutes each time, with relatively fixed tasks and agendas for each meeting)
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hamilton Depression Scale (17-items) Total Score Change
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
The Hamilton Depression Scale (17-items), is a 17 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.
It's considered the gold standard for rating depression severity and used frequently in clinical trials.
Higher HAM-D17 score indicates more severe depression.
A reduction of 50% or more in total score from Baseline indicates clinical response.
|
Baseline,4,8,12 weeks after treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change of The Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
The BRIAN comprises 18 items, which are divided in 3 areas: sleep and social rhythms, activities and eating pattern.
The total score ranged from 18 to 72, a higher score suggested a more severe biological rhythm disturbance.
|
Baseline,4,8,12 weeks after treatment
|
|
Neuroimaging
Tijdsspanne: Baseline,12 weeks after treatment
|
MRI
|
Baseline,12 weeks after treatment
|
|
Skin potential
Tijdsspanne: Baseline,12 weeks after treatment
|
In a quiet environment, the subject's left hand was pre connected to a portable skin potential acquisition device to collect skin potential signals under different types of emotional stimulation task paradigms.
After denoising, 10 time-domain eigenvalues and 8 time-frequency domain eigenvalues were obtained for each task.
|
Baseline,12 weeks after treatment
|
|
Polysomnography
Tijdsspanne: Baseline,12 weeks after treatment
|
overnight polysomnography
|
Baseline,12 weeks after treatment
|
|
Change of the Brief Social Rhythm Scale (BSRS) score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
The BSRS assess the irregularity with which participants engage in basic daily activities during the workweek and on the weekend, using a scale ranging from 1 (very regularly) to 6 (very irregularly)
|
Baseline,4,8,12 weeks after treatment
|
|
Neuropsychological tests
Tijdsspanne: Baseline,12 weeks after treatment
|
Software testing (Prisoner's Dilemma game, Social searching task)
|
Baseline,12 weeks after treatment
|
|
Change of Beck Scale of Suicidal Ideation score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
Beck Scale of Suicidal Ideation is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week.
The BSI score ranges from 0 to 63, with higher scores indicating worse outcomes and lower scores indicating better outcomes.
|
Baseline,4,8,12 weeks after treatment
|
|
Change of the Pittsburgh Sleep Quality Index (PSQI) score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
The PSQI is a validated self-report questionnaire assessing sleep quality and disturbance over 1 month, quantifying 7 sleep-related domains, with higher scores indicating worse sleep quality.
|
Baseline,4,8,12 weeks after treatment
|
|
Change of the Young Mania Rating Scale (YMRS) score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
The Young Mania Rating Scale (YMRS) , is a 11 item diagnostic questionnaire used to measure the severity of mania symptom in patients with mood disorders.
|
Baseline,4,8,12 weeks after treatment
|
|
Change of Hamilton Anxiety Scale score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
Hamilton Anxiety Scale is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients.
Each item on the scale is rated on a 5-point scale from 0 (not present) to 4 (severe), with the total score ranging from 0 to 68.
The HAMA-17 is often used in clinical and research settings to assess the severity of anxiety symptoms and to evaluate the effectiveness of treatments for anxiety.
|
Baseline,4,8,12 weeks after treatment
|
|
Change of the Sociaty Adaptive Scale score
Tijdsspanne: Baseline,4,8,12 weeks after treatment
|
SAS is a self-rating scale used to assess an individual's social functioning in areas such as work, study, interpersonal communication, and family life.
|
Baseline,4,8,12 weeks after treatment
|
|
blood
Tijdsspanne: Baseline,12 weeks after treatment
|
Blood samples are collected to analyze the expression levels of peripheral circadian clock genes (PER1/PER2/PER3/BMAL1).
|
Baseline,12 weeks after treatment
|
|
saliva samples
Tijdsspanne: Baseline,12 weeks after treatment
|
Saliva is employed for the analysis of cortisol and melatonin
|
Baseline,12 weeks after treatment
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Bipolaire en aanverwante stoornissen
- Psychische aandoening
- Stemmingsstoornissen
- Bipolaire stoornis
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, gefuseerd ring
- Heterocyclische verbindingen, 3-ring
- Dibenzothiazepines
- Thiazepines
- Thiepins
- Quetiapine-fumaraat
- Farmaceutische voorbereidingen
Andere studie-ID-nummers
- IIT20250074C-R2
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .